Non-motor subtypes of Early Parkinson Disease in the Parkinson s Progression Markers Initiative

Similar documents
The Parkinson Progression Marker Initiative (PPMI) WW-ADNI July

PPMI Cognitive-Behavioral Working Group. Daniel Weintraub, MD

CSF Aβ1-42 predicts cognitive impairment in de novo PD patients

PPMI Data Overview. Christopher S. Coffey The University of Iowa. PPMI Investigators Meeting May 13-14, 2015 New York, NY

PPMI Status Update. Ken Marek. WW-ADNI July 11, 2013

III./3.1. Movement disorders with akinetic rigid symptoms

Learnings from Parkinson s disease: Critical role of Biomarkers in successful drug development

UDS version 3 Summary of major changes to UDS form packets

Pa t h w a y s. Pa r k i n s o n s. MacMahon D.G. Thomas S. Fletcher P. Lee M. 2006

Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn

Parkinson s Disease in the Elderly A Physicians perspective. Dr John Coyle

The PD You Don t See: Cognitive and Non-motor Symptoms

USING PRECISION MEDICINE TO HELP PATIENTS WITH PARKINSON S DISEASE. The Michael J. Fox Foundation for Parkinson s Research

Case Report Hyperechogenicity of the Substantia Nigra in Parkinson s Disease: Insights from Two Brothers with Markedly Different Disease Durations

Ian McKeith MD, F Med Sci, Professor of Old Age Psychiatry, Newcastle University

Indications. DBS for Tremor. What is the PSA? 6/08/2014. Tremor. 1. Tremor. 2. Gait freezing/postural instability. 3. Motor fluctuations

Study of Verbal Working Memory in Patients with Parkinson s Disease

Non-motor symptoms in Thai Parkinson s disease patients: Prevalence and associated factors

Can Tango Help Improve Quality of Life for Patients with Parkinson s Disease?

The Parkinson s You Can t See

Early Clinical Features of Parkinson s Disease and Related Disorders. Dr. Alastair Noyce

Update on the DLB Module. ADC Directors Meeting Baltimore, MD October 14-15, 2016

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology

Vague Neurological Disorders

Kinematic Modeling in Parkinson s Disease

Parkinson s Disease. Sirilak yimcharoen

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology

Objectives. RAIN Difficult Diagnosis 2014: A 75 year old woman with falls. Case History: First visit. Case History: First Visit

The PD You Don t See: Cognitive and Non-motor Symptoms

Program Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York

Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee

Clinimetrics, clinical profile and prognosis in early Parkinson s disease Post, B.

Evaluation of Parkinson s Patients and Primary Care Providers

Professor K Ray Chaudhuri

Basal ganglia motor circuit

ROLE AND IMPORTANCE OF REHABILITATION TREATMENT IN PATIENTS WITH PARKINSON S DISEASE VODA, Ioana¹; DOGARU, Gabriela¹, ²

Disclaimer. Dialogue with a Patient 3/18/2016

Early Onset Parkinson s Disease: What NPs need to know

02/04/2015. The structure of the talk. Dementia as a motor disorder. Movement, cognition & behaviour. Example 1. Example 2

PARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada

Original Articles. Calne, resting tremor. Mortimer, Pirozzolo, Hansch, & Webster, postural disturbance III

Optimizing Clinical Communication in Parkinson s Disease:

FOUNDATION OF UNDERSTANDING PARKINSON S DISEASE

MAXIMIZING FUNCTION IN PARKINSON S DISEASE

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits

UNDERSTANDING PARKINSON S DISEASE

Does Resistance Training Improve Mobility in Patients with Parkinson s Disease?

World Journal of Pharmaceutical and Life Sciences WJPLS

Change the size of any window by dragging the lower left corner. Use controls

Treatment of Parkinson s Disease: Present and Future

A Longitudinal Evaluation of Health-Related Quality of Life of Patients with Parkinson s Disease

VL VA BASAL GANGLIA. FUNCTIONAl COMPONENTS. Function Component Deficits Start/initiation Basal Ganglia Spontan movements

Form B3L: UPDRS Part III Motor Examination 1

Update on the DLB Module. ADC Directors Meeting Baltimore, MD October 14-15, 2016

05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century

Behavioral Aspects of Parkinson s Disease

Prior Authorization with Quantity Limit Program Summary

The Person: Dementia Basics

Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.

PPMI Genetics Cohorts

Multiple choice questions: ANSWERS

Headway Victoria Epilepsy and Parkinson s Centre

Quality ID #291: Parkinson s Disease: Cognitive Impairment or Dysfunction Assessment National Quality Strategy Domain: Effective Clinical Care

Evaluating the Driving Ability in Patients with Parkinson s Disease Using a Driving Simulator

Big Data and Parkinson s Disease: Exploration, Analyses, and Data Challenges.

Imaging biomarkers for Parkinson s disease

Parkinsons Disease & Movement Disorder Aug 11-13, Frankfurt l Dr. Geeta Shroff

PARKINS ON CENTER. Parkinson s Disease: Diagnosis and Management. Learning Objectives: Recognition of PD OHSU. Disclosure Information

NUMERATOR: All patients with a diagnosis of Parkinson s Disease who were assessed for cognitive impairment or dysfunction in the past 12 months

Correlation between motor and cognitive functions in the progressive course of Parkinson s disease

CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE

Evaluation and Management of Parkinson s Disease in the Older Patient

8/28/2017. Behind the Scenes of Parkinson s Disease

How to Diagnose Early (Prodromal) Lewy Body Dementia. Ian McKeith MD, FRCPsych, F Med Sci.

Cognitive-Motor Interference in Persons with Parkinson Disease

UPDATE ON RESEARCH IN PARKINSON S DISEASE

Is Safinamide Effective as an Add-on Medication in Treating Parkinson's Disease Motor Symptoms?

Parkinson s Disease. Patients will ask you. 8/14/2015. Objectives

Case Study 2: Neurological Degenerative Disease FDA Regulatory and Clinical Background

Postural instability Hypokinesia Rigidity Tremor Forward flexed posture. pain million people 50+ years old 10 most populated countries

First described by James Parkinson in his classic 1817 monograph, "An Essay on the Shaking Palsy"

Sleeping with PD. Jean Tsai, MD PhD September 27, 2014

Clinical Differences Among Four Common Dementia Syndromes. a program of Morningside Ministries

Draft agreed by Scientific Advice Working Party 26 October Adopted by CHMP for release for consultation 09 November

Parkinson s Disease Current Treatment Options

Motor Fluctuations in Parkinson s Disease

University of Alberta

Chairperson: Wen Liu. Carl Luchies. Kelly Lyons. Yvonne Colgrove

DIFFERENTIAL DIAGNOSIS SARAH MARRINAN

European Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations

Deep Brain Stimulation Surgery for Parkinson s Disease

symptoms of Parkinson s disease EXCEPT.

2016 Physician Quality Reporting System Data Collection Form: Parkinson s Disease (for patients aged 18 and older)

Designing patient-centered clinical trials: Results of the MDIC project to use patient preference information to design clinical trials

Non-motor symptoms as a marker of. Michael Samuel

PARKINSON S PROGRESSION MARKERS INITIATIVE. PPMI 2018 Annual Investigators Meeting PPMI Data Blitz

Clinical Trial Results Posting

WELCOME. Parkinson s 101 for the Newly Diagnosed. Today s Topic: Parkinson s Basics presented by Cari Friedman, LCSW

Margaret Schenkman, PT, PhD, FAPTA University of Colorado, Denver Colorado

Enhanced Primary Care Pathway: Parkinson s Disease

Transcription:

Non-motor subtypes of Early Parkinson Disease in the Parkinson s Progression Markers Initiative Samay Jain, MD MSc Seo Young Park, PhD University of Pittsburgh Department of Neurology and Center for Research on Health Care Data Center Funding Sources: Michael J. Fox Foundation for Parkinson s Research, 1 K23 NS070867

Background Parkinson disease (PD) affects over 1 million Americans, with annual costs of $25 billion Diagnosis by clinical exam with characteristic movement disorder Over half of neurons in the substantia nigra pars compacta affected Non-motor features occur in 90% of patients and manifest years prior to motor signs

Background Non-motor features Autonomic disorders Blood pressure changes Constipation Cognitive impairment Sleep and smell disorders Psychiatric complications Non-specific, no biomarker Not ascribed to PD until motor features apparent

Background PD includes varied constellations of motor and non-motor features PD subtypes Defined for motor phenotypes Tremor-predominant Postural Instability and Gait Disorders Slow motor progression / Fast motor progression

Background Can PD subtypes be defined by non-motor features? Non-motor features contribute more to morbidity, institutionalization and costs More comprehensive and holistic management How early could non-motor subtypes be recognized? Non-motor features occur before motor features Earlier diagnosis Earlier treatment

Objective To explore whether subtypes of Parkinson disease (PD) may be defined by non-motor features in a well-characterized cohort of recently diagnosed PD patients

Methods The Parkinson s Progression Markers Initiative (PPMI) Observational cohort which currently contains 345 individuals with PD: at least 30 years old at baseline diagnosed within last 2 years not treated for PD (no medication effects)

Methods PPMI to be carried out over five years 24 sites in United States, Europe, and Australia 400 PD and 200 controls Mean rates change and variability in clinical, imaging, and biomic measures Comparisons between PD, controls and SWEDD s Prodromal cohort recently added http://www.ppmi-info.org

Methods Cluster Analysis Grouping objects so that objects in the same group are more similar in some way to each other than those in other groups Defined similarity by nonmotor features

Methods Sleep Disturbance Epworth Sleepiness Scale REM Sleep Disorder Questionnaire Psychiatric Disturbance Geriatric Depression Scale Impulsive-Compulsive disorders screen Anxiety State and Trait Autonomic dysfunction (SCOPA-AUTO) Disease Progression (MDS-UPDRS 1-3/mo) University of Pennsylvania Smell ID Test Variables used to cluster Non-motor Questionnaire (MDS_UPRDS 1) Cognitive Measures Benton Judgement of Line Orientation Hopkins Verbal Learning Test Letter Number Sequencing Test Montreal Cognitive Assessment Test Semantic Fluency Symbol Digit Modalities Test Age of onset

Methods K-means clustering Partition observations into a pre-specified number of clusters in which each observation belongs to the cluster with the nearest mean Means = Non-motor variables How do we decide the number of clusters?

Methods Sum of squared error (SSE) Used to see if clusters exist, and the # of clusters SSE = sum of squared distance between each member of a cluster and its mean Compare the SSE of randomized data to SSE of actual data for an increasing number of clusters If a data set has strong clusters, the SSE of the actual data should decrease more quickly than random data The point at which difference between the SSE of random vs. actual data stops increasing determines the number of clusters

Methods A 4 cluster solution was selected

Methods Is there a way to graphically demonstrate clusters? Principal Components Analysis (PCA) scree plot Orthogonal transformation = convert a set of observations of possibly correlated variables into linearly uncorrelated variables = principle components The first principle component accounts for as much of the variability as possible Each succeeding component accounts for as much variability as possible provided it be orthogonal to (uncorrelated with) preceding components Different linear combinations (coefiicients) of all cluster variables form each component

Results Variable Component 1 Component 2 Age -0.332-0.225 Coefficients of linear combinations comprising principal components and PCA plot REM -0.183 0.303 SCOPA-AUTO -0.206 0.396 MDS-UPDRS 1-0.177 0.520 Epworth -0.150 0.379 Disease Progression -0.194 0.080 Impulsivity -0.074 0.303 Depression -0.043 0.151 Anxiety 0.016-0.201 Smell ID Test 0.195 0.199 Benton Line 0.219-0.004 MOCA 0.281 0.146 Semantic Fluency 0.357 0.124 Letter Number 0.362 0.063 Verbal Learning 0.374 0.141 Digit Symbol 0.387 0.157 The first 2 components account for 34.36% of the point variability

Results PD Participant Characteristics, Mean (SD) Non-motor characteristics N=313 Age 59.6 Hoehn and Yahr 1.6 MDS-UPDRS-1 6.0 MDS-UPDRS-2 6.0 MDS-UPDRS-3 20.0 # women (%) 109 (35%) SWEDD 39 (12%)

Feature (Mean(SD)) Worst= Best= ALL N=313 (100%) Cluster 1 N=119 (38%) Cluster 2 N=42 (13%) Cluster 3 N=52 (17%) Cluster 4 N=100 (32%) MDS-UPRDS-1 6.0 (4.3) 5.2 (3.2) 13.3 (4.1) 5.1 (2.9) 4.4 (2.9) Sleep - Epworth - REM 6.3 (3.9) 5.3 (2.7) 6.0 (3.1) 5.1 (2.5) 10.6 (4.1) 7.4 (2.9) 6.3 (4.4) 6.2 (3.0) 5.0 (3.1) 4.3 (1.9) Autonomic-SCOPA 13.7 (10.0) 13.4 (7.1) 26.7 (15.2) 13.4 (7.2) 8.8 (6.0) Depression (>5 abnormal) 5.3 (1.4) 4.9 (1.1) 6.2 (2.1) 5.2 (1.3) 5.4 (1.2) Impulsivity/Compulsivity 68 (22%) 19 (16%) 24 (57%) 8 (15%) 17 (17%) Anxiety 46.6 (3.8) 46.2 (3.5) 45.2 (4.5) 48.3 (3.9) 46.7 (3.7) Cognitive - Line Judgment - Verbal Learning - Letter-number - MOCA (>26 normal) - Sematic Fluency - Symbol Digit 12.9 (2.2) 14.7 (2.5) 10.5 (2.7) 27.2 (2.2) 48.0 (11.1) 41.6 (9.9) 13.3 (1.7) 14.8 (2.0) 10.3 (2.0) 27.2 (1.9) 47.2 (8.4) 41.3 (6.5) 12.2 (2.5) 14.2 (2.3) 9.4 (2.5) 27.3 (2.3) 45.2 (9.3) 39.1 (10.4) 11.2 (2.5) 11.9 (2.3) 8.0 (2.2) 25.1 (2.6) 37.4 (7.8) 29.6 (7.4) 13.6 (1.6) 16.4 (1.8) 12.6 (2.1) 28.3 (1.5) 55.8 (10.8) 48.5 (7.7) Smell ID 23.0 (8.5) 21.3 (7.4) 25.6 (8.7) 17.3 (8.1) 26.9 (7.8) Age 59.6 (10.1) 63.3 (6.8) 59.7 (9.7) 68.3 (7.1) 50.8 (8.3) Progression (per mo) 2.4 (2.5) 2.3 (2.0) 3.6 (3.3) 3.2 (3.5) 1.6 (1.4) 1 st symptom to diagnosis (mo) 16.9 (22.5) 15.3 (13.9) 15.8 (15.6) 12.6 (15.6) 21.5 (33.2) Women (N(%)) 109 (35%) 34 (29%) 18 (43%) 14 (37%) 43 (43%) SWEDD (N) (% of SWEDD s) 39 (12% of total) 7 (18%) 14 (36%) 5 (13%) 13 (33%)

Feature (Mean(SD)) Results Motor features of clusters ALL N=313 (100%) Cluster 1 N=119 (38%) Cluster 2 N=42 (13%) Cluster 3 N=52 (17%) Posture 0.3 0.4 0.5 0.5 0.2 Hypokinesia 0.7 0.8 0.8 0.8 0.7 Tremor 0.4 0.5 0.4 0.5 0.4 Motor Features at diagnosis - Tremor - Rigidity - Bradyknesia - Postural Instability - Left side affected - Right side affected - Both sides affected N (%) 245 (81%) 222 (71%) 256 (82%) 27 (8.6%) 119 (38%) 182 (58%) 11 (3.5%) 98 (92%) 89 (75%) 98 (82%) 12 (10%) 51 (43%) 60 (50%) 8 (7%) 37 (88%) 25 (56%) 35 (83%) 8 (19%) 12 (29%) 28 (67%) 2 (5%) 41 (79%) 33 (63%) 40 (77%) 2 (4%) 16 (31%) 36 (39%) 0 Cluster 4 N=100 (32%) 78 (78%) 75 (75%) 83 (83%) 5 (5%) 40 (40%) 58 (58%) 1(1%) Hoehn and Yahr Stage 1.6 (0.5) 1.6 (0.5) 1.6 (0.5) 1.7 (0.5) 1.4 (0.5) Tremor and bradykinesia are common at the time of diagnosis Bilateral involvement of motor features in early PD is rare

Results Main Findings in untreated early PD 4 PD subtypes based on non-motor features 1. Intermediate burden of non-motor features (38%) 2. Non-cognitive, non-motor impairments with fastest progression (13%) Most severe sleep, depressive and autonomic symptoms with highest prevalence of impulsive/compulsive features 3. Cognitive and olfactory most impaired (17%) Most severe olfactory and cognitive deficits across all measures 4. Younger onset, mildest non-motor features and slowest progression (32%)

Summary Results support the concept that PD is a multi-system, multi-organ disease Not just movement Not just brain, involves other end-organs Such patterns of non-motor features may be present prior to diagnostic motor signs in longitudinal cohorts with incident PD cases Future plans: Cluster with motor only, both motor/non-motor features 2, 3 or 5 cluster solutions Follow PD subtypes longitudinally Biomic and imaging data